Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biol Blood Marrow Transplant ; 17(12): 1804-13, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21669298

ABSTRACT

Numerous mechanisms underlie chronic graft-versus-host disease (cGVHD), including skewing of Th1/Th2 cytokine expression. There are biological differences between early-onset and late-onset cGVHD. To test whether different Th1/Th2 cytokines are associated with early- or late-onset cGVHD, peripheral blood was collected from 63 children enrolled on the Children's Oncology Group Phase III trial ASCT0031 evaluating hydroxychloroquine therapy for newly diagnosed extensive cGVHD. mRNA expression of interferon (IFN)-γ and interleukin (IL)-2, -4, and -10 from stimulated peripheral blood mononuclear cells was evaluated by quantitative polymerase chain reaction. Early-onset cGVHD (n = 33) was characterized by decreased expression of IFN-γ and IL-2 mRNA after nonspecific phorbol 12-myristate 13-acetate-ionomycin stimulation. In contrast, late-onset cGVHD (n = 11) was characterized by decreased expression of IL-4 and IL-2 mRNA after anti-CD3 stimulation of T cells. Receiver-operating characteristic curve analysis revealed that IFN-γ expression was correlated with the absence of early cGVHD (area under the curve [AUC] = 0.77) and that IL-4 (AUC = 0.89) and IL-2 (AUC = 0.84) expression was correlated with the absence of late cGVHD. There was no correlation between cytokine expression and a specific immune cell subset. Increased expression of Foxp3 mRNA was seen in early-onset cGVHD and late controls. The different time-dependent cytokine profiles in patients with newly diagnosed cGVHD suggests that the mechanisms underlying cGVHD are temporally regulated. Although larger validation studies are needed, our data suggest that cytokine profiles have a potential use as biomarkers for the diagnosis of cGVHD.


Subject(s)
Cytokines/immunology , Graft vs Host Disease/immunology , Th1 Cells/immunology , Th2 Cells/immunology , Adolescent , Adult , Child , Child, Preschool , Chronic Disease , Cytokines/blood , Double-Blind Method , Female , Graft vs Host Disease/blood , Graft vs Host Disease/drug therapy , Humans , Hydroxychloroquine/therapeutic use , Infant , Interferon-gamma/biosynthesis , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukins/biosynthesis , Interleukins/genetics , Interleukins/immunology , Male , RNA, Messenger/genetics , RNA, Messenger/immunology , Young Adult
2.
Br J Haematol ; 132(4): 452-8, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16412017

ABSTRACT

Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and, although current therapy is widely effective, relapse remains a significant clinical problem for which new treatment strategies are required. The ligation of Toll-like receptors (TLR) on antigen-presenting cells stimulates the generation of strong T-cell helper type 1 (Th1) adaptive immune responses. Although TLR9 ligation has been shown to enhance immunogenicity of a number of leukaemia cell types, there have been few reports of the effects mediated through other TLR. In this study we analysed both the expression of TLR by B-cell precursor ALL cell lines and the effects of individual TLR ligation on the ability of ALL cells to stimulate allogeneic T cells. While ligation of TLR2, TLR 7 and TLR9 led to detectable changes in ALL costimulatory molecule expression, only TLR2 and TLR9 stimulation influenced T-cell responses. The TLR2 ligand Pam3CysSerLys4 provoked the most significant changes in T-cell response, dramatically augmenting interferon-gamma production. These results suggest that TLR ligands, in addition to TLR9 agonists, may provide a strategy to enhance the generation of anti-ALL immune activity by skewing responding T cells towards a Th1 response.


Subject(s)
Immunotherapy/methods , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Toll-Like Receptors/metabolism , CD40 Antigens/metabolism , Cell Line, Tumor , Cell Proliferation , Guanosine/analogs & derivatives , Guanosine/pharmacology , Humans , Interferon-gamma/immunology , Ligands , Peptidoglycan/pharmacology , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Protein Binding , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Stimulation, Chemical , T-Lymphocytes, Helper-Inducer/immunology , Toll-Like Receptor 1/metabolism , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 3/metabolism , Toll-Like Receptor 4/metabolism , Toll-Like Receptor 5/metabolism , Toll-Like Receptor 7/metabolism , Toll-Like Receptor 9/metabolism
3.
Leuk Res ; 29(6): 711-4, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15863213

ABSTRACT

Bone marrow transplantation (BMT) is the primary curative option for refractory/relapsed pediatric acute lymphoblastic leukemia. Although post-transplantation relapse remains a frequent cause of transplantation failure, the mechanisms underlying this are poorly understood. In this study, we compared allogeneic T cell stimulation induced by sequentially obtained precursor-B acute lymphoblastic leukemia (ALL) samples from a single patient with overt graft versus leukemia (GVL) activity. We observed a loss of T cell stimulatory capacity by post-transplantation relapse samples and changes in expression of MHC and the costimulatory molecule CD137 ligand. This study suggests that escape from immune mechanisms after withdrawal of immune suppression is important to ALL progression.


Subject(s)
Bone Marrow Transplantation/adverse effects , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology , Tumor Escape/immunology , Adolescent , Antigens, CD , Bone Marrow Transplantation/immunology , Fatal Outcome , Humans , Male , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Receptors, Nerve Growth Factor/immunology , Receptors, Tumor Necrosis Factor/immunology , Recurrence , T-Lymphocytes/immunology , Tumor Necrosis Factor Receptor Superfamily, Member 9
SELECTION OF CITATIONS
SEARCH DETAIL
...